These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 11788559)

  • 1. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
    Bauditz J; Wedel S; Lochs H
    Gut; 2002 Feb; 50(2):196-200. PubMed ID: 11788559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
    Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease.
    Mazlam MZ; Hodgson HJ
    Gut; 1992 Jun; 33(6):773-8. PubMed ID: 1624158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease.
    Colpaert S; Vastraelen K; Liu Z; Maerten P; Shen C; Penninckx F; Geboes K; Rutgeerts P; Ceuppens JL
    Eur Cytokine Netw; 2002; 13(4):431-7. PubMed ID: 12517728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
    Tang R; Yang G; Zhang S; Wu C; Chen M
    Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.
    Gasche C; Bakos S; Dejaco C; Tillinger W; Zakeri S; Reinisch W
    J Clin Immunol; 2000 Sep; 20(5):362-70. PubMed ID: 11051278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease.
    Reimund JM; Wittersheim C; Dumont S; Muller CD; Baumann R; Poindron P; Duclos B
    J Clin Immunol; 1996 May; 16(3):144-50. PubMed ID: 8734357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease.
    Louis E; Ribbens C; Godon A; Franchimont D; De Groote D; Hardy N; Boniver J; Belaiche J; Malaise M
    Clin Exp Immunol; 2000 May; 120(2):241-6. PubMed ID: 10792371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.
    Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A
    J Gastroenterol Hepatol; 2002 Feb; 17(2):135-9. PubMed ID: 11966942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A soluble factor produced by lamina propria mononuclear cells is required for TNF-alpha enhancement of IFN-gamma production by T cells.
    Prehn JL; Landers CJ; Targan SR
    J Immunol; 1999 Oct; 163(8):4277-83. PubMed ID: 10510366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn's disease and ulcerative colitis.
    Reimund JM; Allison AC; Muller CD; Dumont S; Kenney JS; Baumann R; Duclos B; Poindron P
    Eur J Clin Invest; 1998 Feb; 28(2):145-50. PubMed ID: 9541129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results.
    Lazzerini M; Martelossi S; Marchetti F; Scabar A; Bradaschia F; Ronfani L; Ventura A
    Aliment Pharmacol Ther; 2007 Feb; 25(4):419-27. PubMed ID: 17269997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.
    Bauditz J; Haemling J; Ortner M; Lochs H; Raedler A; Schreiber S
    Gut; 1997 Apr; 40(4):470-4. PubMed ID: 9176073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.
    Plevy SE; Landers CJ; Prehn J; Carramanzana NM; Deem RL; Shealy D; Targan SR
    J Immunol; 1997 Dec; 159(12):6276-82. PubMed ID: 9550432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease.
    Noguchi M; Hiwatashi N; Liu Z; Toyota T
    Gut; 1998 Aug; 43(2):203-9. PubMed ID: 10189845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.
    Carvalho AT; Souza H; Carneiro AJ; Castelo-Branco M; Madi K; Schanaider A; Silv F; Pereira Junior FA; Pereira MG; Tortori C; Dines I; Carvalho J; Rocha E; Elia C
    World J Gastroenterol; 2007 Apr; 13(15):2166-73. PubMed ID: 17465495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10.
    Kucharzik T; Lügering N; Weigelt H; Adolf M; Domschke W; Stoll R
    Clin Exp Immunol; 1996 Jun; 104(3):483-90. PubMed ID: 9099934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
    Reimund JM; Dumont S; Muller CD; Kenney JS; Kedinger M; Baumann R; Poindron P; Duclos B
    Gut; 1997 Apr; 40(4):475-80. PubMed ID: 9176074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor and IL-1 beta expression in pediatric patients with inflammatory bowel disease.
    Olson AD; Ayass M; Chensue S
    J Pediatr Gastroenterol Nutr; 1993 Apr; 16(3):241-6. PubMed ID: 8492249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls.
    Bouma G; Oudkerk Pool M; Scharenberg JG; Kolkman JJ; von Blomberg BM; Scheper RJ; Meuwissen SG; Peña AS
    Scand J Gastroenterol; 1995 Nov; 30(11):1095-100. PubMed ID: 8578170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.